lg 100268 has been researched along with Experimental Mammary Neoplasms in 6 studies
LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bexarotene treatment at a dose of 250 mg/kg diet was associated with reductions in tumor multiplicity of 84% (P < 0." | 1.33 | Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas. ( Brose, HL; Gould, MN; Haag, JD; Hitt, AA; Hu, R; Kim, K; Lindstrom, MJ; Lubet, RA; Mau, B; Monson, DM; Steele, VE; Waller, JL; Watson, PA; Woditschka, S; Zheng, Y, 2006) |
| " We also show that it is not necessary to administer Arz and 268 continuously during tumor progression to prevent cancer in the rat model because dosing of these drugs in combination for relatively short periods, each followed by drug-free rests, is highly effective." | 1.32 | The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. ( Berchuck, A; Heyman, RA; Krajewski, S; Lamph, WW; Liby, K; Reed, JC; Rendi, MH; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liby, K | 3 |
| Risingsong, R | 4 |
| Royce, DB | 3 |
| Williams, CR | 4 |
| Yore, MM | 1 |
| Honda, T | 1 |
| Gribble, GW | 1 |
| Lamph, WW | 3 |
| Vannini, N | 1 |
| Sogno, I | 1 |
| Albini, A | 1 |
| Sporn, MB | 4 |
| Mazumdar, A | 1 |
| Medina, D | 1 |
| Kittrell, FS | 1 |
| Zhang, Y | 1 |
| Hill, JL | 1 |
| Edwards, DE | 1 |
| Bissonnette, RP | 1 |
| Brown, PH | 1 |
| Suh, N | 3 |
| Glasebrook, AL | 1 |
| Grese, TA | 1 |
| Palkowitz, AD | 1 |
| Farris, MR | 1 |
| Heyman, RA | 2 |
| Rendi, MH | 1 |
| Krajewski, S | 2 |
| Reed, JC | 1 |
| Berchuck, A | 1 |
| Woditschka, S | 1 |
| Haag, JD | 1 |
| Waller, JL | 1 |
| Monson, DM | 1 |
| Hitt, AA | 1 |
| Brose, HL | 1 |
| Hu, R | 1 |
| Zheng, Y | 1 |
| Watson, PA | 1 |
| Kim, K | 1 |
| Lindstrom, MJ | 1 |
| Mau, B | 1 |
| Steele, VE | 1 |
| Lubet, RA | 1 |
| Gould, MN | 1 |
| Rendi, M | 1 |
| Lamph, W | 1 |
| Labrie, F | 1 |
| Xu, X | 1 |
| Kim, H | 1 |
| Brown, P | 1 |
6 other studies available for lg 100268 and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2008 |
The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice.
Topics: Animals; Blotting, Western; Bone Density Conservation Agents; Female; Immunoenzyme Techniques; Mamma | 2012 |
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
Topics: Animals; Anticarcinogenic Agents; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Female | 2002 |
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Mammary Neoplasm | 2004 |
Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Body Weight; Disease Models, Animal; Female; Genes, er | 2006 |
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
Topics: Animals; Cell Division; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; H | 2006 |